Document:

<PAGE>
                                                                   Exhibit 10.14

                          VALERA PHARMACEUTICALS, INC.
                             EQUITY INCENTIVE PLAN

          SECTION 1. PURPOSE; DEFINITIONS.  The purposes of the Valera
Pharmaceuticals, Inc. Equity Incentive Plan (the "Plan") are to: (a) enable
Valera Pharmaceuticals, Inc. (the "Company") and its affiliated companies to
recruit and retain highly qualified employees, directors and consultants; (b)
provide those employees, directors and consultants with an incentive for
productivity; and (c) provide those employees, directors and consultants with an
opportunity to share in the growth and value of the Company.

          For purposes of the Plan, the following initially capitalized words
and phrases will be defined as set forth below, unless the context clearly
requires a different meaning:

          a. "Affiliate" means, with respect to a Person, a Person that directly
or indirectly controls, or is controlled by, or is under common control with
such Person.

          b. "Award" means a grant of Options or Restricted Shares pursuant to
the provisions of this Plan.

          c. "Award Agreement" means, with respect to any particular Award, the
written document that sets forth the terms of that particular Award.

          d. "Board" means the Board of Directors of the Company, as constituted
from time to time; provided, however, that if the Board appoints a Committee to
perform some or all of the Board's administrative functions hereunder pursuant
to Section 2, references in this Plan to the "Board" will be deemed to also
refer to that Committee in connection with administrative matters to be
performed by that Committee.

          e. "Cause" means (i) alcohol abuse or use of controlled drugs (other
than in accordance with a physician's prescription); (ii) refusal, failure or
inability to perform any material obligation or fulfill any duty (other than any
duty or obligation of the type described in clause (iv) below) to the Company
(other than due to a Disability), which failure, refusal or inability is not
cured within 10 days after delivery of notice thereof; (iii) gross negligence or
willful misconduct in the course of employment; (iv) any breach of any
obligation or duty to the Company or any of its Affiliates (whether arising by
statute, common law, contract or otherwise) relating to confidentiality,
noncompetition, nonsolicitation or proprietary rights; (v) other conduct
involving any type of disloyalty to the Company or any of its Affiliates,
including, without limitation, fraud, embezzlement, theft or proven dishonesty;
and (vi) conviction of (or the entry of a plea of guilty or nolo contendere to)
a misdemeanor involving moral turpitude or a felony. Notwithstanding the
foregoing, if a Participant and the Company (or any of its Affiliates) have
entered into an employment agreement, consulting agreement or other similar
agreement that specifically defines "cause," then with respect to such
Participant, "Cause" shall have the meaning defined in that employment
agreement, consulting agreement or other agreement.

          f. "Change in Control" means (i) the sale, transfer, assignment or
other disposition (including by merger or consolidation, but excluding any sales
by stockholders made as part of an underwritten public offering of the common
stock of the Company) by stockholders
<PAGE>
of the Company, in one transaction or a series of related transactions, of more
than 50% of the voting power represented by the then outstanding capital stock
of the Company to one or more Persons, (ii) the sale of substantially all the
assets of the Company (other than a transfer of financial assets made in the
ordinary course of business for the purpose of securitization), or (iii) the
liquidation or dissolution of the Company.

          g. "Code" means the Internal Revenue Code of 1986, as amended from
time to time, and any successor thereto.

          h. "Committee" means a committee appointed by the Board in accordance
with Section 2 of this Plan.

          i. "Company" means Valera Pharmaceuticals, Inc.

          j. "Consultant" means an individual performing services as an
independent contractor for the Company, but who is not an Employee or Director.

          k. "Director" means a member of the Board.

          1. "Disability" means a condition rendering a Participant Disabled.

          m. "Disabled" will have the same meaning as set forth in Section
22(e)(3) of the Code.

          n. "Employee" means common-law employee of the Company or any
Subsidiary.

          o. "Exchange Act" means the Securities Exchange Act of 1934, as
amended.

          p. "Fair Market Value" means, as of any date: (i) if the Shares are
not traded in the over-the-counter market, the value of such Shares on that
date, as determined by the Board in its sole and absolute discretion; or (ii) if
the Shares are traded in the over-the-counter market, the Fair Market Value per
Share shall be the mean of the bid and asked prices for a Share on the relevant
valuation date as reported in The Wall Street Journal (or, if not so reported,
as otherwise reported by the National Association of Securities Dealers
Automated Quotations ("NASDAQ") System), as applicable or, if there is no
trading on such date, on the next preceding date on which there were reported
Share prices. In the event Shares are listed on a national or regional
securities exchange or traded through the NASDAQ National Market, the Fair
Market Value of a Share shall be the closing price for a Share on the exchange
or on the NASDAQ National Market, as reported in The Wall Street Journal on the
relevant valuation date, or if there is no trading on that date, on the next
preceding date on which there were reported Share prices.

          q. "Incentive Stock Option" means any Option intended to be and
designated as an "Incentive Stock Option" within the meaning of Section 422 of
the Code.

          r. "Non-Employee Director" will have the meaning set forth in Rule
16b-3(b)(3)(i) promulgated by the Securities and Exchange Commission under the
Exchange Act, or any successor definition adopted by the Securities and Exchange
Commission; provided,

                                       -2-
<PAGE>
however, that the Board or the Committee may, to the extent that it deems
necessary to comply with Section 162(m) of the Code or regulations thereunder,
require that each "Non-Employee Director" also be an "outside director" as that
term is defined in regulations under Section 162(m).

          s. "Non-Qualified Stock Option" means any Option that is not an
Incentive Stock Option.

          t. "Option" means any option to purchase Shares (including Restricted
Shares, if the Committee so determines) granted pursuant to Section 5 hereof.

          u. "Participant" means an employee, consultant or Director of the
Company or any of its Affiliates to whom an Award is granted.

          v. "Person" means an individual, partnership, corporation, limited
liability company, trust, joint venture, unincorporated association, or other
entity or association.

          w. "Restricted Shares" means Shares that are subject to restrictions
pursuant to Section 7 hereof.

          x. "Share" means a share of Company's common stock, par value $.001,
subject to substitution or adjustment as provided in Section 3(c) hereof.

          y. "Stock Purchase Agreement" means any stock purchase, stock
restriction, shareholders' or other agreement the Board may require a
Participant to execute as a condition of his or her receipt of either a grant of
Restricted Shares or of the issuance of Shares pursuant to the exercise of an
Option.

          z. "Subsidiary" means, in respect of the Company, a subsidiary
company, whether now or hereafter existing, as defined in Sections 424(f) and
(g) of the Code.

          SECTION 2. ADMINISTRATION.  The Plan will be administered by the
Board; provided, however, that the Board may at any time appoint a Committee to
perform some or all of the Board's administrative functions hereunder; and
provided further, that the authority of any Committee appointed pursuant to this
Section 2 will be subject to such terms and conditions as the Board may
prescribe and will be coextensive with, and not in lieu of, the authority of the
Board hereunder.

          Any Committee established under this Section 2 will be composed of not
fewer than two members, each of whom will serve for such period of time as the
Board determines; provided, however, that if the Company has a class of
securities required to be registered under Section 12 of the Securities Exchange
Act of 1934, all members of any Committee established pursuant to this Section 2
will be Non-Employee Directors. From time to time the Board may increase the
size of the Committee and appoint additional members thereto, remove members
(with or without cause) and appoint new members in substitution therefor, fill
vacancies however caused, or remove all members of the Committee and thereafter
directly administer the Plan.

                                       -3-
<PAGE>
          Members of the Board who are eligible for Awards or have received
Awards may vote on any matters affecting the administration of the Plan or the
grant of Awards, except that no such member will act upon the grant of an Award
to himself or herself, but any such member may be counted in determining the
existence of a quorum at any meeting of the Board during which action is taken
with respect to the grant of Awards to himself or herself.

          The Board will have full authority to grant Awards under this Plan. In
particular, the Board will have the authority:

          a. to select the persons to whom Awards may from time to time be
granted hereunder (consistent with the eligibility conditions set forth in
Section 4);

          b. to determine the type of Award to be granted to any person
hereunder;

          c. to determine the number of Shares, if any, to be covered by each
such Award;

          d. to establish the terms and conditions of each Award Agreement;

          e. to determine whether and under what circumstances an Option may be
exercised without a payment of cash under Section 5(d); and

          f. to determine whether, to what extent and under what circumstances
Shares and other amounts payable with respect to an Award may be deferred either
automatically or at the election of the Participant.

          The Board will have the authority to adopt, alter and repeal such
administrative rules, guidelines and practices governing the Plan as it, from
time to time, deems advisable; to interpret the terms and provisions of the Plan
and any Award issued under the Plan (and any Award Agreement); to amend the
terms of any Award Agreement, provided that the Participant consents to such
amendment; and to otherwise supervise the administration of the Plan. The Board
may correct any defect, supply any omission or reconcile any inconsistency in
the Plan or in any Award in the manner and to the extent it deems necessary to
carry out the intent of the Plan.

          All decisions made by the Board pursuant to the provisions of the Plan
will be final and binding on all persons, including the Company and
Participants. No member of the Board will be liable for any good faith
determination, act or omission in connection with the Plan or any Award.

          SECTION 3. SHARES SUBJECT TO THE PLAN

          a. Shares Subject to the Plan.  The Shares to be subject to Options or
Restricted Shares under the Plan will be authorized and unissued Shares of the
Company, whether or not previously issued and subsequently acquired by the
Company. The maximum number of Shares that may be subject to Options or
Restricted Shares under the Plan is Two Million Five Hundred Thousand
(2,500,000), and the Company will reserve for the purposes of the Plan, out of
its authorized and unissued Shares, such number of Shares.

                                       -4-
<PAGE>
          b. Effect of the Expiration or Termination of Awards.  If and to the
extent that an Option expires, terminates or is canceled or forfeited for any
reason without having been exercised in full, the Shares associated with that
Option will again become available for grant under the Plan. Similarly, if any
Restricted Share is canceled, forfeited or repurchased for any reason, or if any
Share is withheld pursuant to Section 9(d) in settlement of a tax withholding
obligation associated with an Award, that Share will again become available for
grant under the Plan. Finally, if any Share is received in satisfaction of the
exercise price payable upon exercise of an Option, that Share will become
available for grant under the Plan.

          c. Other Adjustment.  In the event of any recapitalization, stock
split or combination, stock dividend or other similar event or transaction
affecting the Shares, equitable substitutions or adjustments may be made by the
Board, in its sole and absolute discretion, to the aggregate number, type and
issuer of the securities reserved for issuance under the Plan, to the number,
type and issuer of Shares subject to outstanding Options, to the exercise price
of outstanding Options, and to the number, type and issuer of Restricted Shares.

          d. Change in Control.  Notwithstanding anything to the contrary set
forth in this Plan, upon or in anticipation of any Change in Control, the Board
may, in its sole and absolute discretion and without the need for the consent of
any Participant, take one or more of the following actions contingent upon the
occurrence of that Change in Control: (i) cause all outstanding Options to
become fully vested and immediately exercisable; (ii) cause all outstanding
Restricted Shares to become non-forfeitable; (iii) cancel any Option in exchange
for an option to purchase common stock of any successor corporation, which new
option satisfies the requirements of Treas. Reg. Section 1.425-l(a)(4)(i)
(notwithstanding the fact that the original Option may never have been intended
to satisfy the requirements for treatment as an Incentive Stock Option), (iv)
cancel any Restricted Shares in exchange for restricted shares of the common
stock of any successor corporation, (v) redeem any Restricted Share for cash
and/or other substitute consideration with a value equal to the Fair Market
Value of an unrestricted Share on the date of the Change in Control; (vi) cancel
any Option in exchange for cash and/or other substitute consideration with a
value equal to (A) the number of Shares subject to that Option, multiplied by
(B) the difference between the Fair Market Value per Share on the date of the
Change in Control and the exercise price of that Option.

          SECTION 4. ELIGIBILITY.  Employees, directors, consultants, and other
individuals who provide services to the Company or its Affiliates are eligible
to be granted Awards under the Plan. Persons who are not employees of the
Company or a Subsidiary are eligible to be granted Awards, but are not eligible
to be granted Incentive Stock Options.

          SECTION 5. OPTIONS.  Options granted under the Plan may be of two
types: (i) Incentive Stock Options or (ii) Non-Qualified Stock Options. Any
Option granted under the Plan will be in such form as the Board may from time to
time approve.

          The Award Agreement evidencing any Option will incorporate the
following terms and conditions and will contain such additional terms and
conditions, not inconsistent with the terms of the Plan, as the Board deems
appropriate in its sole and absolute discretion:

                                       -5-
<PAGE>
          a. Option Price.  The exercise price per Share purchasable under a
Non-Qualified Stock Option will be determined by the Board. The exercise price
per Share purchasable under an Incentive Stock Option will be not less than 100%
of the Fair Market Value of a Share on the date of the grant. However, any
Incentive Stock Option granted to any Participant who, at the time the Option is
granted, owns more than 10% of the voting power of all classes of shares of the
Company or of a Subsidiary will have an exercise price per Share of not less
than 110% of Fair Market Value per Share on the date of the grant.

          b. Option Term.  The term of each Option will be fixed by the Board,
but no Option will be exercisable more than 10 years after the date the Option
is granted. However, any Incentive Stock Option granted to any Participant who,
at the time such Option is granted, owns more than 10% of the voting power of
all classes of shares of the Company or of a Subsidiary may not have a term of
more than five years. No Option may be exercised by any person after expiration
of the term of the Option.

          c. Exercisability.  Options will vest and be exercisable at such time
or times and subject to such terms and conditions as determined by the Board at
the time of grant. If the Board provides, in its discretion, that any Option is
exercisable only in installments, the Board may waive such installment exercise
provisions at any time at or after grant, in whole or in part, based on such
factors as the Board determines, in its sole and absolute discretion.

          d. Method of Exercise.  Subject to the exercise provisions under
Section 5(c) and the termination provisions set forth in Section 6, Options may
be exercised in whole or in part at any time and from time to time during the
term of the Option, by giving written notice of exercise to the Company
specifying the number of Shares to be purchased. Such notice will be accompanied
by payment in full of the purchase price, either by certified or bank check, or
such other means as the Board may accept and by an executed copy of a Stock
Purchase Agreement, as required by the Board. As determined by the Board, in its
sole discretion, at or after grant, payment in full or in part of the exercise
price of an Option may be made in the form of previously acquired Shares based
on the Fair Market Value of the Shares on the date the Option is exercised;
provided, however, that, in the case of an Incentive Stock Option, the right to
make a payment in the form of previously acquired Shares may be authorized only
at the time the Option is granted.

          No Shares will be issued upon exercise of an Option until full payment
therefor has been made. A Participant will not have the right to distributions
or dividends or any other rights of a shareholder with respect to Shares subject
to the Option until the Participant has given written notice of exercise, has
paid in full for such Shares, and, if requested, has given the representation
described in Section 9(a) hereof.

          e. Incentive Stock Option Limitations.  In the case of an Incentive
Stock Option, the aggregate Fair Market Value (determined as of the time of
grant) of the Shares with respect to which Incentive Stock Options are
exercisable for the first time by the Participant during any calendar year under
the Plan and/or any other plan of the Company or any Subsidiary will not exceed
$100,000. For purposes of applying the foregoing limitation, Incentive Stock
Options will be taken into account in the chronological order in which they were
granted. Any Option not meeting such limitation will be treated for all purposes
as a Non-Qualified Stock Option.

                                       -6-
<PAGE>
          f. Termination of Service.  Unless otherwise specified in the Award
Agreement, Options will be subject to the terms of Section 6 with respect to
exercise upon termination of service.

          g. Transferability of Options.  Except as may otherwise be
specifically determined by the Board with respect to a particular Non-Qualified
Stock Option, no Option will be transferable by the Participant other than by
will or by the laws of descent and distribution, and all Options will be
exercisable, during the Participant's lifetime, only by the Participant or, in
the event of his Disability, by his personal representative.

          SECTION 6. TERMINATION OF SERVICE.  Unless otherwise specified with
respect to a particular Option in the applicable Award Agreement, all Options
will remain exercisable after termination of employment only to the extent
specified in this Section 6.

          a. Termination by Reason of Death.  If a Participant's service with
the Company or any Affiliate terminates by reason of death, any Option held by
such Participant may thereafter be exercised, to the extent then exercisable or
on such accelerated basis as the Board may determine, at or after grant, by the
legal representative of the estate or by the legatee of the Participant under
the will of the Participant, for a period expiring (i) at such time as may be
specified by the Board at or after the time of grant, or (ii) if not specified
by the Board, then 12 months from the date of death, or (iii) if sooner than the
applicable period specified under (i) or (ii) above, then upon the expiration of
the stated term of such Option.

          b. Termination by Reason of Disability.  If a Participant's service
with the Company or any Affiliate terminates by reason of Disability, any Option
held by such Participant may thereafter be exercised by the Participant or his
personal representative, to the extent it was exercisable at the time of
termination, or on such accelerated basis as the Board may determine at or after
grant, for a period expiring (i) at such time as may be specified by the Board
at or after the time of grant, or (ii) if not specified by the Board, then 12
months from the date of termination of service, or (iii) if sooner than the
applicable period specified under (i) or (ii) above, then upon the expiration of
the stated term of such Option.

          c. Cause.  If a Participant's service with the Company or any
Affiliate is terminated for Cause: (i) any Option not already exercised will be
immediately and automatically forfeited as of the date of such termination, and
(ii) any Shares for which the Company has not yet delivered share certificates
will be immediately and automatically forfeited and the Company will refund to
the Participant the Option exercise price paid for such Shares, if any.

          d. Other Termination.  If a Participant's service with the Company or
any Affiliate terminates for any reason other than death, Disability or Cause,
any Option held by such Participant may thereafter be exercised by the
Participant, to the extent it was exercisable at the time of such termination,
or on such accelerated basis as the Board may determine at or after grant, for a
period expiring (i) at such time as may be specified by the Board at or after
the time of grant, or (ii) if not specified by the Board, then 90 days from the
date of termination of service, or (iii) if sooner than the applicable period
specified under (i) or (ii) above, then upon the expiration of the stated term
of such Option.

                                       -7-
<PAGE>
          SECTION 7. RESTRICTED SHARES

          a. Issuance.  Restricted Shares may be issued either alone or in
conjunction with other Awards. The Board will determine the time or times within
which Restricted Shares may be subject to forfeiture, and all other conditions
of such Awards.

          b. Awards and Certificates.  The Award Agreement evidencing the grant
of any Restricted Shares will contain such terms and conditions, not
inconsistent with the terms of the Plan, as the Board deems appropriate in its
sole and absolute discretion. The prospective recipient of an Award of
Restricted Shares will not have any rights with respect to such Award, unless
and until such recipient has executed an Award Agreement and has delivered a
fully executed copy thereof to the Company, and has otherwise complied with the
applicable terms and conditions of such Award. The purchase price for Restricted
Shares may, but need not, be zero.

          A share certificate will be issued in connection with each Award of
Restricted Shares. Such certificate will be registered in the name of the
Participant receiving the Award, and will bear the following legend and/or any
other legend required by this Plan, the Award Agreement, the Company's
shareholders' agreement, or by applicable law:

          THE TRANSFERABILITY OF THIS CERTIFICATE AND THE SHARES REPRESENTED
          HEREBY ARE SUBJECT TO THE TERMS AND CONDITIONS OF THE VALERA
          PHARMACEUTICALS, INC. EQUITY INCENTIVE PLAN AND AN AGREEMENT ENTERED
          INTO BETWEEN [THE PARTICIPANT] AND VALERA PHARMACEUTICALS, INC. (WHICH
          TERMS AND CONDITIONS MAY INCLUDE, WITHOUT LIMITATION, CERTAIN TRANSFER
          RESTRICTIONS, REPURCHASE RIGHTS AND FORFEITURE CONDITIONS). COPIES OF
          THAT PLAN AND AGREEMENT ARE ON FILE IN THE PRINCIPAL OFFICES OF VALERA
          PHARMACEUTICALS, INC. AND WILL BE MADE AVAILABLE TO THE HOLDER OF THIS
          CERTIFICATE WITHOUT CHARGE UPON REQUEST TO THE SECRETARY OF VALERA
          PHARMACEUTICALS, INC.

          Share certificates evidencing Restricted Shares will be held in
custody by the Company or in escrow by an escrow agent until the restrictions
thereon have lapsed. As a condition to any Restricted Share Award, the
Participant may be required to deliver to the Company a share power, endorsed in
blank, relating to the Shares covered by such Award.

          c. Restrictions and Conditions.  The Restricted Shares awarded
pursuant to this Section 7 will be subject to the following restrictions and
conditions:

               (i) During a period commencing with the date of grant of an Award
of Restricted Shares and ending at such time or times as specified by the Board
(the "Restriction

                                       -8-
<PAGE>
Period"), the Participant will not be permitted to sell, transfer, pledge,
assign or otherwise encumber Restricted Shares awarded under the Plan. The Board
may condition the lapse of restrictions on Restricted Shares upon the continued
employment or service of the recipient, the attainment of specified individual
or corporate performance goals, or such other factors as the Board may
determine, in its sole and absolute discretion.

               (ii) Prior to the expiration of the Restriction Period, the
Participant will not be entitled to vote such Restricted Shares. Consistent with
Section 3(c), any distributions or dividends paid in the form of securities with
respect to Restricted Shares will be subject to the same terms and conditions as
the Restricted Shares with respect to which they were paid, including, without
limitation, the same Restriction Period.

               (iii) Subject to the applicable provisions of the Award
Agreement, if a Participant's service with the Company terminates prior to the
expiration of the Restriction Period, all of that Participant's Restricted
Shares which then remain subject to forfeiture will be forfeited.

               (iv) In the event of hardship or other special circumstances of a
Participant whose service with the Company is involuntarily terminated (other
than for Cause), the Board may, in its sole discretion, waive in whole or in
part any or all remaining restrictions with respect to such Participant's
Restricted Shares, based on such factors as the Board may deem appropriate.

               (v) If and when the Restriction Period expires without a prior
forfeiture of the Restricted Shares (or if and when the restrictions applicable
to Restricted Shares lapse pursuant to Sections 3(d) or 7(c)(iv)), the
certificates for such Shares will be replaced with new certificates, without the
portion of restrictive legends described in Section 7(b) applicable to such
lapsed restrictions, and such new certificates will be promptly delivered to the
Participant, the Participant's representative (if the Participant has suffered a
Disability), or the Participant's estate or heir (if the Participant has died).

          SECTION 8. AMENDMENTS AND TERMINATION.  The Board may amend, alter or
discontinue the Plan at any time, but, except as otherwise provided in Section
3(d) of the Plan, no amendment, alteration or discontinuation will be made which
would impair the rights of a Participant with respect to an Award, without that
Participant's consent, or which, without the approval of such amendment within
365 days of its adoption by the Board, by a majority of the votes cast at a duly
held shareholder meeting at which a quorum representing a majority of the
Company's outstanding voting shares is present (either in person or by proxy),
would: (i) increase the total number of Shares reserved for the purposes of the
Plan (except as otherwise provided in Section 3(c)), or (ii) change the persons
or class of persons eligible to receive Awards.

          SECTION 9. GENERAL PROVISIONS.

          a. The Board may require each Participant to represent to and agree
with the Company in writing that the Participant is acquiring securities of the
Company for investment purposes and without a view to distribution thereof and
as to such other matters as the Board

                                       -9-
<PAGE>
believes are appropriate. The certificate evidencing any Award and any
securities issued pursuant thereto may include any legend which the Board deems
appropriate to reflect any restrictions on transfer and compliance with
securities laws.

          All certificates for Shares or other securities delivered under the
Plan will be subject to such share-transfer orders and other restrictions as the
Board may deem advisable under the rules, regulations, and other requirements of
the Securities Act of 1933, as amended, the Exchange Act, any stock exchange
upon which the Shares are then listed, and any other applicable Federal or state
securities laws, and the Board may cause a legend or legends to be put on any
such certificates to make appropriate reference to such restrictions.

          b. Nothing contained in the Plan will prevent the Board from adopting
other or additional compensation arrangements, subject to shareholder approval
if such approval is required; and such arrangements may be either generally
applicable or applicable only in specific cases.

          c. The adoption of the Plan will not confer upon any employee of the
Company or an Affiliate any right to continued employment with the Company or
such Affiliate, nor will it interfere in any way with the right of the Company
or such Affiliate to terminate the employment of any of its employees at any
time.

          d. No later than the date as of which an amount first becomes
includible in the gross income of the Participant for federal income tax
purposes with respect to any Award under the Plan, the Participant will pay to
the Company, or make arrangements satisfactory to the Board regarding the
payment of, any federal, state or local taxes of any kind required by law to be
withheld with respect to such amount. Unless otherwise determined by the Board,
the minimum required withholding obligations may be settled with Shares,
including Shares that are part of the Award that gives rise to the withholding
requirement. The obligations of the Company under the Plan will be conditioned
on such payment or arrangements and the Company will, to the extent permitted by
law, have the right to deduct any such taxes from any payment of any kind
otherwise due to the Participant.

          SECTION 10. EFFECTIVE DATE OF PLAN.  This Plan will become effective
on the date that it is adopted by the Board; provided, however, that if the Plan
is not approved by a majority of the votes cast at a duly held shareholder
meeting at which a quorum representing a majority of the Company's outstanding
voting shares is present (either in person or by proxy) within 12 months before
or after the date of the Board's adoption, any Option intended to qualify as an
Incentive Stock Option will be treated for all purposes as a Non-Qualified Stock
Option.

          SECTION 11. TERM OF PLAN.  This Plan will continue in effect until
terminated in accordance with Section 8; provided, however, that no Incentive
Stock Option will be granted hereunder on or after the 10th anniversary of (i)
the date of shareholder approval of the Plan or (ii) the date the Plan is
adopted by the Board, whichever is earlier; but provided further, that Incentive
Stock Options granted prior to such 10th anniversary may extend beyond that
date.

          SECTION 12. INVALID PROVISIONS.  In the event that any provision of
this Plan is found to be invalid or otherwise unenforceable under any applicable
law, such invalidity or

                                      -10-
<PAGE>
unenforceability will not be construed as rendering any other provisions
contained herein as invalid or unenforceable, and all such other provisions will
be given full force and effect to the same extent as though the invalid or
unenforceable provision was not contained herein.

          SECTION 13. GOVERNING LAW.  This Plan and all Awards granted hereunder
will be governed by and construed in accordance with the laws and judicial
decisions of the State of Delaware, without regard to the application of the
principles of conflicts of laws.

          SECTION 14. BOARD ACTION.  Notwithstanding anything to the contrary
set forth in this Plan, any and all actions of the Board or Committee, as the
case may be, taken under or in connection with this Plan and any agreements,
instruments, documents, certificates or other writings entered into, executed,
granted, issued and/or delivered pursuant to the terms hereof, will be subject
to and limited by any and all votes, consents, approvals, waivers or other
actions of all or certain stockholders of the Company or other persons required
by:

          a. the Company's Articles of Incorporation (as the same may be amended
and/or restated from time to time);

          b. the Company's Bylaws (as the same may be amended and/or restated
from time to time); and

          c. any other agreement, instrument, document or writing now or
hereafter existing, between or among the Company and its stockholders or other
persons (as the same may be amended from time to time).

          SECTION 15. NOTICES.  Any notice to be given to the Company pursuant
to the provisions of the Plan shall be addressed to the Company in care of its
Secretary (or such other person as the Company may designate from time to time)
at its principal executive office, and any notice to be given to a Participant
shall be delivered personally or addressed to him or her at the address given
beneath his or her signature on his or her Award Agreement, or at such other
address as such Participant may hereafter designate in writing to the Company.
Any such notice shall be deemed duly given on the date and at the time delivered
via personal, courier or recognized overnight delivery service or, if sent via
telecopier, on the date and at the time telecopied with confirmation of delivery
or, if mailed, on the date five days after the date of the mailing (which shall
be by regular, registered or certified mail). Delivery of a notice by telecopy
(with confirmation) shall be permitted and shall be considered delivery of a
notice notwithstanding that it is not an original that is received.

               ADOPTION AND APPROVAL OF PLAN

               Date Plan adopted by Board: September 23,2002

               Date Plan approved by Stockholders: September 23, 2002

               Effective Date of Plan: September 23,2002

                                      -11-<PAGE>
                                                                   Exhibit 10.17

                                    AGREEMENT

                                  Introduction

          AGREEMENT made this 30th day of November, 1989, between National
Patent Development Corporation, a Delaware corporation and all of its
subsidiaries and affiliates now and hereafter formed ("National Patent"), and
Dento-Med Industries, Inc., a New York corporation and all of its subsidiaries
and affiliates now and hereafter formed ("Dento-Med").

                                    Recitals

          WHEREAS, National Patent and Dento-Med are currently parties to an
Agreement, dated June 25, 1976, among National Patent, Dento-Med, Applied Health
Services, Inc., Hydron Dental Products, Inc. ("Hydron Dental") and AHDM, as
amended by a letter agreement, dated May 24, 1983, from National Patent, NPD
Dental, Inc., the successor to Hydron Dental ("NPD"), to Dento-Med, as further
amended by a letter agreement, dated December 30, 1987, from National Patent and
NPD to Dento-Med (hereinafter collectively referred to as the "Existing
Agreement");

          WHEREAS, National Patent and Dento-Med desire to enter into this
Agreement and to replace the Existing Agreement with respect to the future
rights of the parties;

          WHEREAS, it is the desire of the parties to settle all proceedings now
pending between them;

          NOW, THEREFORE, in consideration of the mutual covenants hereinafter
contained, the parties hereto agree as follows:

          1. Definitions.  As used in this Agreement, the following capitalized
terms and non-capitalized terms shall have the respective meanings assigned to
them below:

          "Agreement" shall mean this Agreement, together with all schedules and
exhibits hereto, as the same may be supplemented, modified, amended or restated
from time to time in the manner provided herein.

          "Closing" shall mean the date of execution and delivery of this
Agreement.

          "Consumer Field" shall mean cosmetic products as defined in Section
201(i) of the Federal Food, Drug and Cosmetic Act, as well as, hand and skin
creams or lotions, anti-perspirants, sun screens, hair and scalp shampoos or
conditioners, fragrances, soaps, bug or insect repellants or makeup. The term
Consumer Field shall not include any Products which contain prescription or
nonprescription drugs (for example, hand and skin creams which contain a
prescription or nonprescription drug).
<PAGE>
          "Dento-Med" shall have the meaning assigned to it in the Introduction.

          "DMI Common Stock" shall have the meaning assigned to it in Section
4(a).

          "Existing Agreement" shall have the meaning assigned to it in the
Recitals.

          "Hydrocryl" shall mean the product containing a multi-component
system, one component comprising of a small amount of a solid methacrylate
polymer, and the second component comprising a liquid reactive monomer mixture
capable of polymerization and of forming a Polymer, and such product shall be
used solely in connection with the fabrication, assembly or dealing with natural
or artificial dentures.

          "Hydrolon" shall mean the trademark or tradename heretofore or
hereafter referred to as "Hydrolon" by National Patent or Dento-Med, including
without limitation the common law trademarks "Hydrolon Polymers", "Hydrolon
Fragrance", and "Hydrolon Breath Freshener".

          "Hydron" shall mean the trademark or tradename heretofore or hereafter
referred to as "Hydron" by National Patent or Dento-Med.

          "National Patent" shall have the meaning assigned to it in the
Introduction.

          "New Product" shall have the meaning assigned to it in Section 2(d).

          "NPDC Common Stock" shall have the meaning assigned to it in Section
4(a).

          "Oral Health Field" shall mean any Product, for use in the mouth, on
the lips (excluding prescription and nonprescription drugs for lip sores and
oral ulcers) or gums or otherwise in the areas of the body of humans and/or
animals referred to as the oral cavity or in connection with natural or
artificial dentures, in the fabrication, assembly or dealing with dentures, for
use by dentists or related practitioners including drugs and devices.

          "other Company" shall have the meaning assigned to it in Section 4(e).

          "Polymer(s)" shall mean polymeric containing materials comprised of
polymerized hydroxyethyl methacrylate or hydroxyethyl acrylate, including but
not limited to, (i) homopolymers and copolymers obtained by the polymerization
of hydroxyethyl methacrylate or hydroxyethyl acrylate, (ii) any mixture or alloy
containing as a component any polymer comprising polymerized hydroxyethyl
methacrylate or hydroxyethyl acrylate, and (iii) any fabricated product,
formulation, cosmetic, recipe, list of ingredients, and the like containing as a
component any polymer comprising polymerized hydroxyethyl methacrylate or
hydroxyethyl acrylate.

                                       -2-
<PAGE>
          "Products" shall mean all products which are composed wholly or
partially of Polymer or produced with the use of Polymer.

          "Registrable Securities" shall have the meaning assigned to it in
Section 4(e).

          "Registrant" shall have the meaning assigned to it in Section 3(g).

          2. License.  (a) Exclusive License.  Subject to the terms of this
Agreement, National Patent hereby grants to Dento-Med an exclusive worldwide
license with the right to grant sublicences thereunder, in respect to National
Patent's right, title and interest in and to presently owned or subsequently
issued patents and the Hydron trademark, for the lives thereof, to manufacture,
market, or use the Product in the Consumer Field, the Oral Health Field and for
any New Products which Dento-Med acquires the exclusive rights under Section
2(d) hereof. National Patent shall, as soon as reasonably practicable, disclose
in writing to Dento-Med any and all such patents and trademarks, as such shall
arise or as such exists at this time.

          (b) National Patent's Rights.  National Patent shall have the
exclusive right to manufacture, sell or distribute any prescription drug or
medical device (including hearing aids and related items), as those terms are
defined in Sections 20l(g)(l) and (h), respectively, of the Federal Food, Drug
and Cosmetic Act, each made with a Polymer, but shall not have the right to sell
or distribute any Product in the Oral Health Field, except for prescription drug
Products for lip sores and oral ulcers. National Patent shall also have the
exclusive right to manufacture, sell or distribute any Product listed on
Schedule A hereto or any Product in the fields listed on Schedule A hereto.

          (c) Limits on Competition by National Patent and Dento-Med.  National
Patent hereby covenants that it will not (i) sell or distribute any Products or
New Products or (ii) use the Hydron trademark, in the Consumer Field or the Oral
Health Field. National Patent further covenants that it will not (i) sell any
Polymers to any person for resale in the Consumer Field or the Oral Health Field
or (ii) transfer the Polymer technology to any person for the purpose of selling
Products or New Products in the Consumer Field or the Oral Health Field.
Dento-Med hereby covenants that it will not (i) sell or distribute any Products
or New Products or (ii) use the Hydron trademark, in any of the areas that
National Patent has exclusive rights under Section 2(b) hereof. Dento-Med
further covenants that it will not (i) sell any Polymers to any person for
resale in any of the areas that National Patent has exclusive rights under
Section 2(b) hereof or (ii) transfer the Polymer technology to any person for
the purpose of selling Products or New Products in any of the areas that
National Patent has exclusive rights under Section 2(b) hereof.

          (d) Rights to Other Products.  Except as set forth herein, Dento-Med
and National Patent shall not be precluded from the manufacture, exploitation,
use, assignment, sale or licensing of any nonprescription drug Product
(nondescription drug

                                       -3-
<PAGE>
Products will be determined based upon the active ingredient included not the
disease it will be indicated for, i.e., each party can use different
nonprescription drugs to treat the same disease) or any other product containing
Polymer not included in Section 2(a) or 2(b) hereof (the "New Product").
Dento-Med or National Patent may obtain a one-year exclusive right to
manufacture, market or use such New Product by notifying the other party hereto
of such New Product, which notice shall describe the New Product in detail and
shall demonstrate that the party is making a legitimate and bona fide effort to
manufacture, market or use such New Product. On the date hereof, National Patent
has notified Dento-Med of two active ingredients for nonprescription drug
Products which it desires to exploit and Dento-Med has accepted them. Within
thirty (30) days of the date hereof, Dento-Med shall notify National Patent of
ten (10) active ingredients for nonprescription drug Products which it desires
to exploit and National Patent shall accept them. Except as set forth above,
neither party shall have the right to give notices with respect to more than
three (3) New Products at any time (each active ingredient for a nonprescription
drug Product shall count as one New Product). The one-year exclusive period may
be extended for three months if the party giving the notice began commercially
marketing the New Product or demonstrates that it is negotiating in good faith
with a third party or an affiliate to market such New Product. In the event the
exclusive period expires, the party that received such exclusive period may
request a new exclusive period, provided that (i) six (6) months have passed
since the expiration of the exclusive period, (ii) the party has followed the
notice requirements of this Section 2(d), and (iii) the other party had not
submitted a notice for such New Product during the intervening six-month period.
If such party begins commercially marketing or enters into an agreement with a
third party to market (although the marketing of the New Product by such third
party need not take place within the time period described above, but must take
place within three and one-half (3 1/2) years of the date of the original
notice) the New Product within the period described above, such party shall have
exclusive rights to such New Product as if it were a product described in
Section 2(a) or 2(b) above. Notwithstanding the foregoing, each of Dento-Med and
National Patent shall have nonexclusive rights to any New Product if the party
manufacturing, marketing or using such New Product has not followed the notice
requirements of this Section 2(d) or the exclusive period has expired.

          (e) Trademarks.  (i) To the extent that Dento-Med is the assignee of
the Hydron trademark, Dento-Med hereby reassigns to National Patent all of its
title in and to the trademark Hydron, and National Patent agrees to maintain
such trademark throughout the world so that Dento-Med shall continue to have the
right to enjoy its exclusive license to use, assign or sublicense under such
trademark as set forth in section 2(a) hereof. In the event National Patent does
not seek renewal of any or all registrations of such trademark, National Patent
shall notify Dento-Med of such 60 days prior to the end of the registration
period or periods so that Dento-Med shall have an opportunity to renew the
trademark; and National Patent shall promptly assign the full title in and to
that trademark to Dento-Med and Dento-Med, at its expense, may complete, execute
and file all forms and papers required in order to perfect such assignment.
National Patent agrees to cooperate in the perfecting of

                                       -4-
<PAGE>
such assignments. In the event National Patent elects to withdraw from the
business of manufacturing the Polymer as contemplated by Section 5(c) hereof,
National Patent shall promptly assign the full right, title and interest in and
to that trademark to Dento-Med and Dento-Med, at its expense, may complete,
execute and file all forms and papers as required by Dento-Med's counsel in
order to perfect such assignment.

               (ii) National Patent shall assign the full right, title and
interest in and to the trademark Hydrolon to Dento-Med and Dento-Med, at its
expense, may complete, execute and file all forms and papers as required by
Dento-Med's counsel in order to perfect such assignment in any trademark office
in the world.

          (f) Research.  Upon the request of Dento-Med. National Patent shall
cooperate with Dento-Med in the research and synthesization on Dento-Med's
behalf of new products and making other modifications of the Polymers suggested
by Dento-Med. Dento-Med and National Patent agree to arrange a reasonable work
schedule for Dento-Med's use of a portion of National Patent's Hydro-Med
Sciences facilities, under the supervision of Hydro-Med Sciences personnel, for
each research product but National Patent shall be permitted to limit the use of
its facilities to thirty days in each calendar year, but not in excess of five
days in any calendar month. National Patent shall be permitted to deny Dento-Med
use of its Hydro-Med Sciences facilities if National Patent shall have a
reasonable basis to object to Dento-Med's research project based on governmental
and environmental regulations which will be violated by such research project.
National Patent shall not be required to conduct research with fragrances.
Dento-Med shall promptly reimburse National Patent for an amount equal to twenty
percent (20%) in excess of National Patent's (i) labor, (ii) materials and (iii)
supply costs incurred in connection with the research. Dento-Med shall have all
rights to file for patents for such technology resulting from such research and
National Patent shall give all reasonable assistance to Dento-Med or Dento-Med's
patent counsel in that respect. National Patent shall be permitted to practice
the technology in such patents or any existing patents or hereafter issued
patents of Dento-Med for use solely in the manufacture, marketing or sale of any
Products or New Products described in Section 2(b) or 2(d) hereof.

          3. Royalties.  (a) Amount of Royalty. Except as provided in Section
3(c) hereof with regard to nonprescription drug Products, Dento-Med and National
Patent agree that in the event that any Product or any New Product, other than
any Products or fields listed on Schedule A hereto, is marketed by any third
party or parties or by either Dento-Med or National Patent, as permitted
hereunder, a royalty of five (5%) percent of National Patent's or Dento-Med's
(as the case may be) net sales (i.e. revenues received in cash or other form)
for such Products shall be paid to the other party hereto.

               (b) Sale to Affiliates.  Except as provided in Section 3(c)
hereof with regard to nonprescription drug Products, in the event Dento-Med or
National Patent sells any Product or New Product to an affiliate, the net sales
price for determining the royalty to be paid for such Product shall be the fair
market value of

                                      -5-
<PAGE>
such Product, i.e., the price an unrelated third party would have paid for such
product. In the event Dento-Med and National Patent cannot agree on the fair
market price of such product, both Dento-Med and National Patent shall agree on
a third party who shall determine the fair market price of the Product. The
decision rendered by the third party shall be final, conclusive and binding. For
purposes of this Section 3(b), affiliate shall have the meaning assigned to it
in the General Rules and Regulations under the Securities Act of 1933, as
amended.

               (c) Royalties for Non-Prescription Drugs.  Dento-Med and National
Patent agree that in the event either Dento-Med or National Patent sells any
nonprescription drug Products (other than nonprescription drug Products sold by
National Patent (or to a third party) which constitute the products and fields
set forth in Schedule A) themselves, to an affiliate or to any third party, a
royalty of five (5%) percent of Dento-Med's or National Patent's net sales
(i.e., revenues received in cash or other form), including payments for
research, for such products shall be paid to the other party hereto. If
Dento-Med or National Patent sells a nonprescription drug Products other than
nonprescription drug Products sold by National Patent (or to a third party)
which constitute the Products and fields set forth in Schedule A) to a third
party or parties and receives up-front license fees, royalties or similar
payments (in cash or other form) a royalty of twenty-five (25%) percent of such
payments shall be paid to the other party hereto.

               (d) Payment of Royalties.  All royalties shall be paid within 30
days of the end of each calendar quarter, and shall be accompanied by a report
showing in reasonable detail the calculation of the royalty payment. An
authorized representative will be permitted to inspect the records at reasonable
times for purposes of verifying any information relating to the report.

          4. Exchange of Stock.  (a) The Exchange.  As further consideration for
the above referenced assignments, National Patent is simultaneously delivering
to Dento-Med two hundred thousand (200,000) shares of common stock par value
$.01 of National Patent ("NPDC Common Stock") and Dento-Med is simultaneously
delivering to National Patent one million two hundred thousand (1,200,000)
shares of the common stock par value $.0l of Dento-Med ("DMI Common Stock").

          (b) Restricted Securities.  Dento-Med and National Patent represent
and warrant that each is acquiring the stock described in Section 4(a) for its
own account without a view toward the public distribution or sale thereof,
except in compliance with the registration requirements of the Securities Act of
1933, or an applicable exemption from such requirement(s) and an opinion of
counsel satisfactory to the issuer of such stock that registration thereof is
not required, which opinion shall not be unreasonably withheld.

          (c) Legend.  Dento-Med and National Patent each individually consent
to the placing of a restrictive legend on the certificates representing the
National Patent and Dento-Med stock to be issued pursuant to Section 4(a) of
this

                                      -6-
<PAGE>
Agreement. The restrictive legend to be placed on the certificates representing
the shares of National Patent and Dento-Med stock to be delivered to each other
pursuant to Section 4(a) of this Agreement shall provide:

          "The shares represented by this certificate have been acquired for
          investment and have not been registered under the Securities Act of
          1933. The shares may not be sold or transferred in the absence of such
          registration or an exemption therefrom under said Act."

          (d) Reporting Requirements.  Notwithstanding the provisions of Section
4(b) hereof and without limiting the effectiveness thereof, National Patent and
Dento-Med will each use its respective best efforts to satisfy its respective
reporting obligation pursuant to the Securities Exchange Act of 1934 in order to
permit, when appropriate, sales of its shares owned by the other parties hereto
pursuant to Securities and Exchange Commission Rule 144 and other such rules,
regulations and/or statutes as may be in effect from time to time.

          (e) Registration.  If, at any time after six months from the date
hereof, either Dento-Med or National Patent proposes to file a registration
statement under the Securities Act of 1933, as amended (the company proposing to
file such registration statement hereinafter called the "Registrant" and the
other company hereinafter called the "other Company") with respect to an
offering by the Registrant for its own account or for the account of others of
shares of the Registrant's common stock (other than a registration statement on
forms S-4 or S-8 or any other registration statement pursuant to which the only
shares registered are shares underlying, or issued pursuant to, stock options
issued in connection with the provision to the Registrant of consulting or
similar services), then the Registrant shall in each case give written notice of
such proposed filing to the other Company at least 20 days prior to the
anticipated filing date, and such notice shall offer the other Company the
opportunity to register such number of shares of the Registrant's common stock
issued to the other Company pursuant to this Agreement as the other Company may
request (the shares so requested to be registered hereinafter called the
"Registrable Securities"). The Registrant shall include the Registrable
Securities in any such registration which is not underwritten and shall use its
best efforts to cause the managing underwriter or underwriters of a proposed
underwritten offering to permit the Registrable Securities to be included in
such registration on the same terms and conditions as any similar securities
Registrant included therein. Notwithstanding the foregoing, if the managing
underwriter or underwriters of such offering delivers an opinion to the other
Company that the total amount of securities which they and the Registrant and
any other persons or entities intend to include in such offering is sufficiently
large to materially and adversely affect the success of such offering, then the
amount of securities to be offered for the account of the other Company shall be
reduced to the extent necessary to reduce the total amount of securities to be
included in such offering to the amount recommended by such managing underwriter
or underwriters; provided, however, that if securities are being offered for the
account of other

                                       -7-
<PAGE>
persons or entities as well as the Company, such reduction shall not represent a
greater fraction of the number of securities requested to be offered by the
other Company than the fraction of similar reductions imposed on such other
persons or entities with respect to the amount of securities they request to
offer. In the event that any shares of the other Company are requested by the
other Company to be registered for sale by the Registrant pursuant to the
foregoing provision in the case of a non-underwritten offering, or are in fact
registered for sale pursuant to an effective registration statement, in the case
of an underwritten offering, then the Registrant shall be entitled, on one
occasion only, to request in writing that the other Company register any or all
of the shares issued to the Registrant pursuant to this Agreement, and the other
Company shall then use its best efforts to effect such registration and cause
such registration to become effective within a reasonable time, provided that
either National Patent or Dento-Med shall be entitled, after six months from the
date hereof, on one occasion only, to request in writing that the other company
register any or all shares issued to the company making the request pursuant to
this Agreement, and the other company shall then use its best efforts to effect
such registration and cause such registration to become effective within a
reasonable time, provided, however that (i) these rights shall expire three
years from the date hereof, and (ii) shall be effective only if an exemption
from registration is not available with respect to a proposed sale by the
Registrant of its shares of the other Company's stock. In connection with any
registration pursuant to this Section 4(e), the Registrant and the other Company
shall provide to the other (and if required, to the underwriter) such customary
indemnifications as the party to be indemnified shall reasonably request.
Dento-Med shall not sell more than 50,000 shares of NPDC Common Stock during any
six month period commencing six months from the date hereof except with the
consent of National Patent. If Dento-Med does not sell all of its 50,000 shares
of NPDC Common Stock in any given six-month period, it may sell any of its
remaining shares (unsold in the prior period) in the next six-month period
provided that in no event may Dento-Med sell more than 50,000 shares of NPDC
Common Stock in any sixty-day period. National Patent shall not sell more than
300,000 shares of DMI Common Stock during any six month period commencing six
months from the date hereof except with the consent of Dento-Med. If National
Patent does not sell all of its 300,000 shares of DMI Common Stock in any given
six-month period, it may sell any of its remaining shares (unsold in the prior
period) in the next six-month period provided that in no event may National
Patent sell more than 300,000 shares of DMI Common Stock in any sixty-day
period. The restrictions above shall not apply to any shares of DMI Common Stock
currently held by National Patent.

          (f) Undertakings.  If any shares issued pursuant to this Agreement are
included in a registration statement by virtue of an exercise of the rights
granted by Section 4(e), the party exercising such rights shall (i) be deemed to
have consented to the method of distribution as determined by the issuer or the
underwriter(s) of said securities and shall enter into such agreement(s) as
shall be reasonably required by the issuer or the underwriter(s); (ii) cooperate
with the issuer in the preparation and filing of such registration statement;
(iii) agree to the conduct of the offering in such manner as the issuer may
reasonably deem necessary to insure compliance with

                                       -8-
<PAGE>
Federal and/or State securities laws; (iv) pay all the underwriting discounts
and commissions with respect to the shares of stock being registered for the
party exercising its rights pursuant to Section 4(e); (v) pay all incremental
costs, if any, of the registration incurred as a result of that party's exercise
of its rights pursuant to Section 4(e) (provided that such incremental costs
shall not be computed on a cost per share basis but shall include only those
directly attributable to shares of stock being registered as a result of the
party's exercise of its rights pursuant to Section 4(e) hereof); and (vi)
indemnify the issuer, each of its directors, each of its officers who have
signed the registration statement and each person, if any, who controls, the
issuer within the meaning of the Securities Act of 1933 against liabilities
which may arise as a result of or in connection with the information supplied by
the party exercising its rights pursuant to Section 4(e) in connection with said
registration statement(s).

          (g) Irrevocable Proxy.  (i) National Patent hereby agrees to grant to
Dento-Med an irrevocable proxy to vote, for any purpose whatsoever, the
1,200,000 shares of DMI Common Stock it is acquiring, with such proxy to
terminate with respect to any shares sold by National Patent in normal brokerage
transactions to a non-affiliate, upon such sale. This proxy shall cover all or
any part of the shares that National Patent owns and shall own from time to time
hereafter.

               (ii) Dento-Med hereby agrees to grant to National Patent an
irrevocable proxy to vote, for any purpose whatsoever, the 200,000 shares of
NPDC Common Stock it is acquiring, with such proxy to terminate with respect to
any shares sold by Dento-Med in normal brokerage transactions to a
non-affiliate, upon such sale. This proxy shall cover all or any part of the
shares that Dento-Med shall own from time to time hereafter.

          (h) Delivery of Stock Certificates, Proxy, etc.  (i) Dento-Med shall
simultaneously deliver to National Patent at the Closing (A) a stock certificate
representing 1,200,000 shares of DMI Common Stock, and (B) a proxy providing
National Patent with all voting rights to the 200,000 shares of NPDC Common
Stock issued to Dento-Med, with such proxy to be in accordance with Section 4(g)
above.

               (ii) National Patent shall simultaneously deliver to Dento-Med
(A) a stock stock certificate representing 200,000 shares of NPDC Common Stock,
and (B) a proxy providing Dento-Med with all voting rights to the 1,200,000
shares of DMI Common Stock issued to National Patent, with such proxy to be in
accordance with Section 4(g) above.

          (i) Standstill.  Each of Dento-Med and National Patent agrees that
neither Dento-Med and its affiliates nor National Patent and its affiliates
shall, directly or indirectly, unless approved by the other: (i) commence a
tender or exchange offer for any securities or acquire any securities of the
other company's stockholders; or (ii) solicit proxies of the other company's
stockholders.

                                       -9-
<PAGE>
          5. Supply of Polymer and Hydrocryl.  (a) Polymer Prices and Supply.
Dento-Med shall have the right to purchase from National Patent Polymers in the
physical forms in which National Patent now makes or will make at any time at no
more than cost (which cost shall consist of labor, materials and overhead
related to the manufacture of such Polymers) plus twenty percent (20%). Without
limiting the foregoing, such sales of Type N Polymer to be made by National
Patent to Dento-Med shall be made at the following rates: $72.00 per kilogram
for purchase orders of up to 1,700 kilograms per calendar year; $60.00 per
kilogram for purchase orders after the initial order(s) of 1700 kilograms and up
to 3,000 kilograms; provided that if a single purchase order, deliverable in
whole or in part within one year, is for a quantity in excess of 1,700
kilograms, the price per kilogram shall be $60.00 per kilogram for that entire
order. The prices and terms of any purchase order of Type N Polymer above 3,000
kilograms will be negotiated between the parties and if the parties are unable
to agree on a price, Dento-Med may purchase any additional quantities of Type N
Polymer from a third party or have the Type N Polymer manufactured by a third
party. Payment shall be made within forty-five (45) days of delivery to
Dento-Med of the materials ordered and delivery shall be made promptly at the
time requested in the purchase order. The delivery date specified on each
purchase order shall be not earlier than ninety (90) days and not later than one
year and no purchase order shall request deliveries in any month in excess of
the higher of 250 kilograms per month or one hundred percent (100%) of the
average quantity ordered in the previous three months. Within ten (10) days of
the receipt of any purchase order, National Patent shall notify Dento-Med
whether National Patent will be able to manufacture and deliver such quantity of
Polymer, and if National Patent notifies Dento-Med that it is unable to
manufacture and deliver such quantity of Polymer, National Patent shall provide
Dento-Med with all manufacturing procedures (including know-how) which National
Patent possesses and has utilized in the past to manufacture such Type N Polymer
itself. The price per kilogram of all Polymers shall be adjusted at the
beginning of each calendar year commencing January 1, 1991 based on the change
in the Consumer Price Index from the prior calendar year to the present calendar
year with respect to labor costs (with National Patent delivering to Dento-Med
the base labor costs for the prior calendar year) and the change in the cost of
the raw materials used in the manufacture of the Polymer, which change in cost
shall be documented with invoices.

          (b) Prices and Supply of the Polymer/Monomer for Hydrocryl.  Dento-Med
shall have the right to purchase from National Patent and National Patent shall
be obligated to supply to Dento-Med the Polymer/Monomer for Hydrocryl in the
physical forms in which National Patent has made, now makes or will make at any
time during the term of this Agreement. Such sales of the Polymer for Hydrocryl
shall be made at the following rates:

               (i) Heat Cure Hydrocryl at $5.58 per pound;

               (ii) Chair Side Hydrocryl at $5.94 per pound; and

                                      -10-
<PAGE>
               (iii) Hydrocryl Lab Repair at $5.94 per pound.

Payment shall be made within forty-five (45) days of delivery to Dento-Med of
the materials ordered and delivery shall be made promptly at the time requested
in the purchase order. The price per kilogram of the Polymer for Hydrocryl shall
be adjusted at the beginning of each calendar year commencing January 1, 1991
based on the change of the Consumer Price Index from the prior calendar year to
the present calendar year with respect to labor costs (with National Patent
delivering to Dento-Med the base labor costs for the prior calendar year), and
the change in the cost of the raw materials used in the manufacture of the
Polymer for Hydrocryl, which change in cost shall be documented with invoices.

          (c) Transfer of Technology; Manufacture of the Polymers.  So long as
National Patent is manufacturing the Polymer, National Patent shall be obligated
to supply and deliver to Dento-Med of up to 3,000 kilograms of the Polymer
requested by Dento-Med at prices consistent with Section 5(a) hereof and
Dento-Med shall be obligated to purchase its first 3,000 kilograms of Polymer
each year from National Patent. In the event National Patent is unable to
manufacture the Polymer as a result of an act of God, fire or other catastrophe
beyond the control of National Patent, National Patent shall assist Dento-Med in
obtaining a substitute supplier of the Polymer or shall provide Dento-Med with
all manufacturing procedures (including know-how) which National Patent
possesses and has utilized in the past to manufacture such Polymers itself. If
National Patent subsequently became able to manufacture, Dento-Med shall within
one (1) year thereof commence repurchasing such requirements of Polymers from
National Patent. In the event Dento-Med requests a certain type of Polymer which
National Patent does not desire to manufacture, National Patent shall provide
Dento-Med or a third party supplier under a confidentiality agreement with all
manufacturing procedures (including know-how) which National Patent possesses
and has utilized in the past to manufacture such type of Polymer and Dento-Med
agrees to use such technology solely to manufacture that type of Polymer.
National Patent shall not be required to manufacture for Dento-Med any Polymer
which is required to be combined at the time of manufacture with a fragrance,
but National Patent shall provide Dento-Med with all manufacturing procedures
(including know-how) which National Patent possesses and has utilized in the
past to manufacture such Polymer (other than Type N Polymer) itself. National
Patent makes no warranty that the manufacturing procedures provided hereunder
will enable Dento-Med to have commercial quantities manufactured. In the event
National Patent elects to withdraw from the business of manufacturing the
Polymer, National Patent shall notify Dento-Med as soon as it reaches such a
decision but in no event less than one year before such termination of
manufacturing, and shall offer to sell to Dento-Med the equipment used in the
manufacturing of the Polymer at the fair market value of such equipment. In the
event National Patent elects to withdraw from the business of manufacturing the
Polymer, then upon the request of Dento-Med, National Patent shall provide
Dento-Med with all manufacturing procedures (including know-how) which National
Patent possesses and has utilized in the past to manufacture such Polymers
itself. In addition, National Patent will render all necessary and reasonable

                                      -11-
<PAGE>
technical assistance to Dento-Med Including all pertinent specifications,
drawings, designs or other documents and provide Dento-Med with information
sufficient to enable Dento-Med to manufacture such particular form or forms of
the Polymers. Dento-Med shall reimburse National Patent for its costs in
rendering such assistance. All transfers of technology by National Patent under
this Agreement shall be made pursuant to confidentiality agreements.

          6. Resolution of Arbitration Proceeding between the Parties.  The
parties shall execute and deliver at the Closing hereof and shall cause to be
filed with the appropriate tribunal forthwith after the Closing hereof
stipulations discontinuing with prejudice the proceeding listed on Exhibit A.

          7. Rights under the Existing Agreement.  The Existing Agreement is
hereby terminated and rescinded with respect to all agreements therein, provided
that all payments and transfers of capital stock consummated thereunder shall
not be returned except as herein set forth. This Agreement shall control in all
respects in connection with any inconsistencies with the Existing Agreement and
with all future actions to be taken by the parties hereunder.

          8. Term.  This Agreement shall continue indefinitely from the date of
the Closing hereof unless otherwise specified in this Agreement.

          9. Miscellaneous.  (a) Notice.  Any notice or other communication
required or permitted under the terms of this Agreement shall be in writing,
shall be transmitted either manually, by mail, by telegram or by facsimile, and
shall be effective when received. Any party may, by notice to the others, change
its address for receiving such notices. The parties designate the following
addresses as its address for the purpose of receiving notice(s) under this
Agreement:

          If to National Patent:

               National Patent Development Corporation
               9 West 57th Street
               New York, NY 10019
               Attn: Jerome I. Feldman, President

          with a copy to:

               Lawrence Gordon, Esq., General Counsel
               (at the same address)

                                      -12-
<PAGE>
          If to Dento-Med:

               Dento-Med Industries, Inc.
               941 Clint Moore Road
               Boca Raton, Florida 33431
               Attn: Harvey Tauman, President

          with a copy to:

               Parker Chapin Flattau & Klimpl
               1211 Avenue of the Americas
               New York, New York 10036
               Attn: Henry I. Rothman, Esq.

          (b) Successors and Assigns: Assignment.  This Agreement shall be
binding upon and inure to the benefit of the parties hereto and their respective
successors and permitted assigns hereunder.

          (c) Waiver.  The waiver of any right arising from any breach of any
representation, warranty, covenants or other term or condition of this Agreement
shall be effective only in the specific instance and for the specific purpose
for which given and shall not be deemed, regardless of frequency given, to be a
further or continuing waiver.

          (d) Modification, Amendment, Etc.  This Agreement shall not be
changed, modified or amended except by a writing signed by the parties whose
rights and/or obligations pursuant to this Agreement are to be changed, modified
or amended. This Agreement may not be discharged except by performance in
accordance with its terms or by a writing signed by the parties hereto.

          (e) Governing Law.  This Agreement, and its validity, construction and
performance, shall be governed in all respects by the laws of the State of New
York without giving effect to principles of conflict of laws and may be executed
in several counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument representing the
agreement of the parties hereto.

          (f) Severability.  In the event that any one or more of the provisions
contained in this Agreement shall be invalid, illegal or unenforceable in any
respect, the validity, legality and enforceability of the remaining provisions
contained herein shall not in any way be affected or impaired thereby.

          10. Arbitration.  The parties hereto agree to arbitrate any dispute
arising under this Agreement, out of or in relation to this Agreement, or any
breach or asserted breach of this Agreement in New York City pursuant to the
rules then obtaining of the American Arbitration Association. Any award rendered
shall be final

                                      -13-
<PAGE>
and conclusive upon the parties and judgment thereon may be entered in the
highest court of the forum, state or federal, having jurisdiction.

          IN WITNESS WHEREOF, the parties hereto have duly executed this
Agreement on the day and year first above written.

ATTEST                                  NATIONAL PATENT DEVELOPMENT CORPORATION

:                                       BY:
  ----------------------------------        ------------------------------------
               (SEAL)

ATTEST                                  DENTO-MED INDUSTRIES, INC.

:                                       BY:
  ----------------------------------        ------------------------------------
               (SEAL)

                                      -14-
<PAGE>
                                   Schedule A

Hydron(R) Wound Dressing (Product)

Hema optical monomer (Product)

Hydron(R) Lens Coating III (Product)

Syncro-Mate-B(R) Implant (Product)

Hydron(R) Wetting Solution for blood tests (Product)

Opthalmic or optical products (Product)

Hydron-300 environmental coating (Product)

Wound Care (field)

Burn Care (field)

A-l Polymer for use in eye care (Products)

Hydron Type NCC Polymer for tissue culture use (Product)

Population Council - drug release of leutinizing hormone --
   releasing hormone and analogs thereof (Product)

                                      -15-
<PAGE>
                                    Exhibit A

                           Case Number 13 168 00170 89

                     National Patent Development Corporation
                          v. Dento-Med Industries, Inc.
                                       and
                           Dento-Med Industries, Inc.
                   v. National Patent Development Corporation

                                      -16-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00079-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00079-of-00352.parquet"}]]